Echinocandin B0 HCI Pharma Grade API is a fermentation-derived cyclic hexapeptide hydrochloride salt supplied under product code EC-B0-HCl-PH.01. The material is specified for solid oral dosage forms—tablet, capsule, and granule—and for injectable compounding where the parenteral-grade release profile is applied. The hydrochloride counterion modifies pH-dependent aqueous solubility without altering the β-(1,3)-D-glucan synthase inhibitory pharmacophore associated with the echinocandin core. The free base is poorly water soluble; the HCl salt is used when aqueous granulation or pH-adjusted reconstitution is required. Oral and injectable presentations are not interchangeable because the injectable grade is additionally controlled for bacterial endotoxin and sub-visible particulate matter. Analytical release methods follow pharmacopoeial general chapters where applicable, including USP <921> Karl Fischer, USP <281> residue on ignition, USP <61>/<62> microbial enumeration, USP <85> bacterial endotoxins, and ISO 13320:2020 for laser diffraction particle size analysis.

Why Does the Hydrochloride Salt Require Different Particle Size Control Than the Free Base in Capsule Filling?

Particle size distribution governs content uniformity and powder flow. The oral grade is released with D₅₀ 20–60 µm and D₉₀ ≤ 100 µm; the injectable grade is micronized to D₉₀ ≤ 20 µm to support reconstitution and filtration. The hydrochloride salt is more hygroscopic than the free base: open-tray exposure at 60% relative humidity increases water content by up to 2.8% w/w within 24 h. Handling is therefore specified below 30% relative humidity. Karl Fischer water content is limited to ≤ 3.0% w/w for oral presentation and ≤ 1.5% w/w for injectable presentation. Bulk density is typically 0.35–0.55 g/mL, tapped density 0.55–0.80 g/mL, and Hausner ratio 1.25–1.45, indicating fair flow that may require dry granulation or roller compaction for high-dose tablets.

Wet granulation in a 25 L high-shear granulator using a 10 mm conical impeller at 400 rpm and a 2.5 mm nozzle diameter is controllable when water volume is maintained between 6% and 8% w/w. Below 6% w/w the granules are friable and produce fines above 40% w/w after 20 min fluid-bed drying at 45°C. Above 8% w/w, torque end-point values rise non-linearly and the milled particle size distribution broadens. Milling through a 0.8 mm Conidur screen at 1400 rpm yields granules with D₅₀ 180–250 µm suitable for tablet compression. Capsule filling is acceptable when the granule flow function coefficient exceeds 4.0 at 1 kPa consolidation stress. These boundaries are batch-log process ranges, not absolute thermodynamic limits; published data for this specific hydrochloride salt is limited.

Lyophilization-Relevant Thermal and Endotoxin Constraints

Injectable presentation requires bacterial endotoxin control below 2.5 EU/mg by USP <85>. The API is not processed by terminal steam sterilization because the cyclic hexapeptide core is susceptible to aqueous hydrolytic degradation above neutral pH. Freeze-drying is the default conversion. Aqueous formulations for lyophilization are maintained between pH 4.5 and 6.0; above pH 7, deamidation and ring-opening degradation accelerate, producing impurities visible by HPLC area normalization. Reconstitution outside this window is a known failure mode in injectable compounding. The collapse temperature of the formulation depends on bulking agents; freeze-drying microscopy should be used to set primary drying shelf temperature. Mannitol at 4% w/v with annealing at -20°C for 2 h produces a rigid cake when the API concentration is 10 mg/mL. Sub-visible particles after reconstitution are controlled by USP <788>. Differential scanning calorimetry of the hydrochloride salt shows a broad endotherm consistent with dehydration between 40°C and 90°C; decomposition onset is not observed below 150°C in sealed-pan data. Residual solvents are monitored by headspace gas chromatography against ICH Q3C Class 2 limits; elemental impurities are controlled by ICH Q3D parenteral permitted daily exposure.

Residual solvent limits are route-specific. For oral and injectable grades, Class 1 solvents such as benzene and carbon tetrachloride must be absent at the limit of detection. Class 2 solvents including methanol, acetonitrile, and dichloromethane are controlled to ≤ 3000 ppm, ≤ 410 ppm, and ≤ 600 ppm, respectively, unless a higher permitted daily exposure is justified by the dosing regimen. Class 3 solvents such as acetone and ethanol are limited to ≤ 5000 ppm or according to process capability. Inhalational or parenteral limits are not automatically applicable to oral grade release. The injectable grade is additionally controlled for sub-visible particulate matter after reconstitution and for container-closure compatibility under USP <800> handling criteria. Elemental impurity data are generated by ICP-MS using matrix-matched standards; cadmium, lead, arsenic, and mercury are monitored to parenteral permitted daily exposure for the injectable grade and to oral permitted daily exposure for oral presentations.

If Roller Compaction Replaces Direct Compression for High-Dose Capsules

Direct compression of the oral grade at API loads above 60% w/w is limited by poor flow and segregation risk. Roller compaction is used instead. Ribbon density is controlled between 1.0 g/cm³ and 1.3 g/cm³; ribbon thickness is set at 2 mm. Milling through a 1.0 mm screen with a rotating impeller at 800 rpm produces granules with D₅₀ 250–350 µm. Blending with crospovidone and microcrystalline cellulose requires 15 min in a bin blender at 12 rpm. Tablet compression at 50–100 MPa yields tensile strength above 1.5 MPa. At compression pressures above 120 MPa, tablet capping and edge chipping occur due to over-compression of the salt. For capsule fill, the same granules are filled to a weight variation of ± 5%. The oral grade is not suitable for high-shear direct compression formulations without a dry granulation step. Process operators should not exceed 30% relative humidity during roller compaction because the hydrochloride salt shows surface moisture uptake that alters ribbon hardness and milled granule size.

Product-Class Differences Across Hydrochloride, Free Base, Acetate, and Sodium Salts

Echinocandin B0 HCl differs from echinocandin B free base mainly in counterion identity and resulting solubility. The free base is poorly water soluble and is more commonly processed by dry granulation or micronization with surfactant. The hydrochloride salt provides pH-dependent solubility suitable for aqueous granulation at pH 4.5–6.0. Compared with caspofungin acetate, which carries an ethylenediamine side chain and is formulated as a parenteral lyophilized salt, echinocandin B0 HCl retains a fermentation-derived B0 nucleus and serves as an API or precursor for further semisynthetic modification. Micafungin sodium differs in counterion, lipophilic side chain, and solution light sensitivity. The table below summarizes processing-class distinctions.

The oral grade and injectable grade must be released against separate specifications. Missing endotoxin data for the oral presentation does not permit injectable use. The injectable grade must not be processed in equipment previously used for oral grade without cleaning verification and endotoxin recovery studies. Use of the hydrochloride salt in semisynthetic routes requires that residual solvent and elemental impurity profiles be revalidated for the downstream final salt. Avoid aqueous pH > 7, relative humidity above 60%, and compression pressure above 120 MPa. The oral grade is not suitable for injectable compounding; the injectable grade is not required for routine oral granule formulation.